Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Omnicell $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million…
Humanigen stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares…
Natera $287.5 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
MDLIVE $50 million private placement
Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series…
Venus Medtech (Hangzhou) HK$1.2 billion H shares placement
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate…
I-Mab $418 million private placement
Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate…
Nestlé $2.6 billion acquisition of Aimmune Therapeutics
Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with…